The FDA approved cemiplimab-rwlc (Libtayo) for treatment of locally advanced, or metastatic, cutaneous squamous cell carcinoma (CSCC). This is the first drug treatment approved for advanced CSCC, the second most common cancer in the U.S. Please see the FDA website for more information.
Recent Posts
- Holiday Health Hazards: Common ER Visits and How to Prevent Them
- What Is a DNP? Everything You Need to Know About the Doctor of Nursing Practice
- Halloween Health & Safety: Tips for Families and Clinicians
- Exploring a Career in Nursing: What You Need to Know
- Back-to-School Wellness — A Resource for Families and Providers